Company announcement - Announcements and Circulars - Investor - XZenith Biopharm

Investor relations

Company announcement Performance presentation

Performance promotion

Company announcement

All

2025 ANNUAL REPORT
VOLUNTARY ANNOUNCEMENT RESULTS OF PRELIMINARY DATA FROM THE PHASE 1B FORTRESS CLINICAL STUDY OF NG-350A PRESENTED AT THE 2026 AACR
VOLUNTARY ANNOUNCEMENT RESULTS OF PHASE III CLINICAL DATA OF DIROZALKIB FOR THE FIRST-LINE TREATMENT OF ALK POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER PRESENTED AT THE 2026 AACR
INSIDE INFORMATION APPROVAL BY THE STOCK EXCHANGE REGARDING THE APPLICATION FOR THE PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION
VOLUNTARY ANNOUNCEMENT APPROVAL TO INITIATE A PHASE III CLINICAL TRIAL FOR NEW INDICATION OF ANAPRAZOLE SODIUM
INSIDE INFORMATION NOTIFICATION LETTER OF THE CSRC REGARDING THE APPLICATION FOR THE PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2026
VOLUNTARY ANNOUNCEMENT - LICENSING AND SUPPLY AGREEMENT WITH BOSTON ONCOLOGY FOR BIREOCICLIB AND DIROZALKIB
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
VOLUNTARY ANNOUNCEMENT FINAL ANALYSIS RESULTS OF THE PHASE 3 CLINICAL STUDY (BRIGHT-2) OF BIREOCICLIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF HR+/HER2- ADVANCED BREAST CANCER PUBLISHED IN TOP-TIER INTERNATIONAL JOURNAL JAMA ONCOLOGY

<1 2 3 4 5 6 >